Unknown

Dataset Information

Do cancer biomarkers make targeted therapies cost-effective? A systematic review in metastatic colorectal cancer.


ABSTRACT:

Background

Recent advances in targeted therapies have raised expectations that the clinical application of biomarkers would improve patient's health outcomes and potentially save costs. However, the cost-effectiveness of biomarkers remains unclear irrespective of the cost-effectiveness of corresponding therapies. It is thus important to determine whether biomarkers for targeted therapies provide good value for money. This study systematically reviews economic evaluations of biomarkers for targeted therapies in metastatic colorectal cancer (mCRC) and assesses the cost-effectiveness of predictive biomarkers in mCRC.

Methods

A literature search was performed using Medline, Embase, EconLit, NHSEED. Papers published from 2000 until June 2018 were searched. All economic evaluation

SUBMITTER: Seo MK 

PROVIDER: S-EPMC6157891 | biostudies-literature | 2018

REPOSITORIES: biostudies-literature